Big Pharma Split Stock Performance
| PRM Stock | CAD 13.29 0.01 0.08% |
The firm shows a Beta (market volatility) of 0.0068, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Big Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Big Pharma is expected to be smaller as well. At this point, Big Pharma Split has a negative expected return of -0.13%. Please make sure to confirm Big Pharma's total risk alpha, as well as the relationship between the kurtosis and day typical price , to decide if Big Pharma Split performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Big Pharma Split has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's primary indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
Forward Dividend Yield 0.0881 | Payout Ratio 0.783 | Forward Dividend Rate 1.24 | Dividend Date 2024-11-08 | Ex Dividend Date 2024-06-28 |
1 | Prediction This Will be Eli Lillys Next Big Move. - The Motley Fool | 09/19/2024 |
2 | Prediction Vertex Pharmaceuticals Could Be The Next Stock Split Stock - 247 Wall St. | 10/31/2024 |
3 | Harvest Declares Big Pharma Split Corp. November 2024 Distribution - Yahoo Finance | 11/22/2024 |
| Begin Period Cash Flow | 819.2 K | |
| Free Cash Flow | 11.9 M |
Big |
Big Pharma Relative Risk vs. Return Landscape
If you would invest 1,454 in Big Pharma Split on September 3, 2024 and sell it today you would lose (125.00) from holding Big Pharma Split or give up 8.6% of portfolio value over 90 days. Big Pharma Split is producing return of less than zero assuming 1.0654% volatility of returns over the 90 days investment horizon. Simply put, 9% of all stocks have less volatile historical return distribution than Big Pharma, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Big Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Big Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Big Pharma Split, and traders can use it to determine the average amount a Big Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1265
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PRM |
Estimated Market Risk
| 1.07 actual daily | 9 91% of assets are more volatile |
Expected Return
| -0.13 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Big Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Big Pharma by adding Big Pharma to a well-diversified portfolio.
Big Pharma Fundamentals Growth
Big Stock prices reflect investors' perceptions of the future prospects and financial health of Big Pharma, and Big Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Big Stock performance.
| Return On Equity | -0.0363 | |||
| Return On Asset | -0.0069 | |||
| Profit Margin | (2.01) % | |||
| Operating Margin | 0.51 % | |||
| Current Valuation | (9.41 M) | |||
| Shares Outstanding | 1.13 M | |||
| Price To Book | 0.95 X | |||
| Price To Sales | 46.87 X | |||
| Revenue | 311.76 K | |||
| Gross Profit | 5.56 M | |||
| EBITDA | (139.68 K) | |||
| Net Income | (645.35 K) | |||
| Total Debt | 10.3 M | |||
| Book Value Per Share | 13.99 X | |||
| Cash Flow From Operations | 11.86 M | |||
| Earnings Per Share | 0.99 X | |||
| Market Capitalization | 15.04 M | |||
| Total Asset | 26.53 M | |||
About Big Pharma Performance
By examining Big Pharma's fundamental ratios, stakeholders can obtain critical insights into Big Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Big Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (545.41) | (572.68) | |
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | (0.01) | (0.01) |
Things to note about Big Pharma Split performance evaluation
Checking the ongoing alerts about Big Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Big Pharma Split help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Big Pharma Split generated a negative expected return over the last 90 days | |
| Big Pharma Split has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 311.76 K. Net Loss for the year was (645.35 K) with profit before overhead, payroll, taxes, and interest of 5.56 M. | |
| Latest headline from news.google.com: Harvest Declares Big Pharma Split Corp. November 2024 Distribution - Yahoo Finance |
- Analyzing Big Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Big Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Big Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Big Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Big Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Big Pharma's stock. These opinions can provide insight into Big Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Big Stock
Big Pharma financial ratios help investors to determine whether Big Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Big with respect to the benefits of owning Big Pharma security.